📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-01 01:50
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
45 announcements match the current filters (relevance ≥ 5).
Sun Pharma Signs US Access Pact; Delays Section 232 Tariffs for Over 2 Years
Sun Pharma has entered into an agreement with the U.S. government at a White House signing ceremony, committing to Most Favored Nation (MFN) pricing for state Medicaid programs and future innovative drug launches. In return, the U.S. government has delayed Section 232 tariffs on Sun Pharma's innovative pharmaceutical products for over two years. The U.S. is Sun Pharma's largest innovative market, contributing approximately 27% of total global revenue (TTM revenue of ₹59,911 Cr), with innovative medicines making up about 22% of company sales.
Confidence: HIGH
What changedSun Pharma committed to MFN pricing for U.S. Medicaid programs in exchange for a 2+ year delay in Section 232 tariffs on its innovative drug portfolio.
Why it mattersThe U.S. generates ~27% of global revenue; shielding its high-growth specialty/innovative portfolio from tariffs provides medium-term revenue predictability in its largest export market.
US share of global revenue: approx. 27%Innovative portfolio share of sales: about 22%Tariff relief duration: over two yearsTTM Revenue (Context): ₹59,911 Cr
📅 Short termProvides positive regulatory clarity and eliminates near-term tariff overhangs on U.S. innovative formulations exports.
📈 Long termSecures institutional access in the U.S. public healthcare channel (Medicaid), though MFN pricing may cap pricing flexibility for future innovative drug launches.
⚠ Risk flags
- Pricing concessions under MFN framework may pressure realisations on future innovative product launches
- Remaining financial and pricing terms of the White House agreement remain confidential
Key Highlights
U.S. government delays Section 232 tariffs on Sun Pharma innovative pharmaceutical products for over 2 years
Company commits to Most Favored Nation (MFN) pricing for state Medicaid programs and future innovative launches
U.S. market accounts for approximately 27% of Sun Pharma's global revenue
Global Innovative Medicines portfolio accounts for about 22% of total company sales
Ranks second by prescriptions in U.S. dermatology
👀 What to Watch
Monitor upcoming quarterly disclosures for gross margin impacts from MFN pricing commitments versus tariff cost savings in the U.S. specialty business.
Sun Pharma Wins US Appeals Court Ruling in Long-Standing Lipitor Antitrust Litigation
The US Court of Appeals for the Third Circuit has ruled entirely in favor of Sun Pharmaceutical Industries Limited and its subsidiaries in the long-standing generic Lipitor (Atorvastatin) antitrust litigation. The appellate court affirmed the US District Court's summary judgment in favor of the company and upheld the denial of class certification to plaintiffs. The litigation pertained to alleged antitrust violations arising from a 2008 patent litigation settlement agreement with Pfizer. This legal victory brings the US antitrust dispute substantially to a close, removing a contingent litigation overhang for the company.
Confidence: HIGH
What changedThe US Court of Appeals affirmed summary judgment favoring Sun Pharma, effectively concluding the generic Lipitor antitrust lawsuit.
Why it mattersEliminates potential unquantified antitrust liability, damages exposure, and legal overhang in the US generics business.
Patent settlement agreement year: 2008Announcement date: 17 August 2026TTM Net Profit (FY26): ₹12,104 Cr
📅 Short termPositive sentiment driver for the stock as a key legacy US litigation overhang is successfully resolved with no financial damages awarded.
📈 Long termRemoves uncertainty around historical settlement practices, allowing management to focus on US specialty product expansion.
⚠ Risk flags
- Subject to any further legal remedies/appeals that may still be available to plaintiffs under US law
Key Highlights
US Court of Appeals for the Third Circuit affirmed summary judgment in entirety in favor of Sun Pharma
Court affirmed the District Court's order denying class certification to the plaintiffs
Litigation concerned a 2008 patent litigation settlement agreement with Pfizer for generic Lipitor (Atorvastatin)
Brings the multi-year US antitrust litigation substantially to a close, subject to any remaining plaintiff legal remedies
👀 What to Watch
Track whether plaintiffs pursue any further appeals or remedies, and monitor quarterly notes to accounts for final derecognition of contingent litigation references.
Sun Pharma Q1 FY27: Sales Up 10.1% to ₹15,184 Cr; India Growth Strong at 16%
Sun Pharma reported a 10.1% YoY revenue growth in Q1 FY27, reaching ₹15,184 Cr, led by a robust 16% growth in the Indian domestic market. While EBITDA margins slightly compressed to 28.9% due to the high base of Lenalidomide sales in the previous year, the Global Innovative Medicine portfolio grew 12.8% to $351 million. The US business faced a 9.7% decline to $427 million, primarily due to generic erosion and competition. The company maintains a strong balance sheet with $3.4 billion in net cash and expects the Organon acquisition to close by Q4 FY27.
Confidence: HIGH
What changedThe company is transitioning to a higher effective tax rate (27.8% vs 24.3%) as India tax benefits exhaust, while simultaneously scaling its specialty portfolio to over 20% of revenue.
Why it mattersSun Pharma's ability to grow its domestic leadership and specialty portfolio is critical to maintaining margins as the US generic business faces pricing pressure and product erosion.
Q1 Consolidated Sales: ₹15,183.6 CrIndia Sales Growth: 16%Innovative Medicine Sales: $351 millionUS Sales Decline: 9.7%Net Cash: $3.4 billionEffective Tax Rate: 27.8%
📅 Short termThe stock may react to the strong domestic performance, though the higher tax rate and US generic decline are near-term headwinds to net profit growth.
📈 Long termStructural shift towards a specialty-led model and the integration of Organon could provide long-term margin stability and global scale.
⚠ Risk flags
- US generic erosion
- Rising effective tax rates
- Integration risks of the Organon acquisition
Key Highlights
India formulation sales grew 16% YoY to ₹5,474.9 Cr, outperforming the Indian Pharmaceutical Market volume growth of 2% with 5.4% volume growth.
Global Innovative Medicine sales reached $351 million, now contributing 21.9% of total consolidated revenue.
Net cash position remains strong at $3.4 billion at the consolidated level as of June 2026.
R&D investment for the quarter stood at ₹826.4 Cr, representing 5.4% of sales, with 30% dedicated to innovative R&D.
India market share increased to 8.5% from 8.2% in the previous period, maintaining the No. 1 rank.
👀 What to Watch
Monitor the ramp-up of new specialty launches like Leqselvi and Unloxcyt to offset US generic erosion, and track the closing of the Organon acquisition expected in Q4 FY27.
CRISIL Reaffirms 'CRISIL AAA/Stable' Rating and Removes Rating Watch
CRISIL Ratings has reaffirmed Sun Pharma's long-term bank facilities at 'CRISIL AAA/Stable' and removed the 'Rating Watch with Developing Implications' status. This watch was originally placed in May 2026 following the company's announcement of strategic corporate actions, including the ₹2,902 Cr acquisition of Taro shares. The reaffirmation of the highest credit rating reflects the company's robust financial profile, characterized by a Debt-to-Equity ratio of 0.61 and TTM PAT of ₹11,488 Cr. This stable outlook confirms the company's capacity to execute its ₹3,000 Cr greenfield expansion without significant credit risk.
Confidence: HIGH
What changedCRISIL removed the 'Developing Implications' watch and assigned a 'Stable' outlook to the existing AAA rating.
Why it mattersIt validates the company's balance sheet strength despite recent large-scale acquisitions and ongoing capital expenditure plans, ensuring low cost of capital.
Credit Rating: CRISIL AAA/StableDebt-to-Equity Ratio: 0.61TTM Revenue: ₹58,462 CrTaro Acquisition Value: ₹2,902 CrGreenfield Expansion: ₹3,000 Cr
📅 Short termNeutral to positive; confirms the absence of credit-related risks following recent M&A activity.
📈 Long termReaffirms the company's structural financial strength and its ability to maintain a dominant market position while expanding its specialty portfolio.
⚠ Risk flags
- US FDA regulatory actions (e.g., Halol facility alert)
- Pricing pressures in international markets
Key Highlights
Rating reaffirmed at 'CRISIL AAA/Stable' for long-term bank facilities
Removed from 'Rating Watch with Developing Implications' status as of August 5, 2026
Company maintains a Debt-to-Equity ratio of 0.61 with ₹13,605 Cr in total debt
TTM Revenue of ₹58,462 Cr provides strong coverage for financial obligations
👀 What to Watch
Monitor the integration of the Taro acquisition and the execution timeline of the ₹3,000 Cr greenfield facility in Madhya Pradesh. The stable AAA rating suggests the company has ample financial headroom for these capital-intensive projects.
₹5.00 Dividend Approved; Innovative Medicines Reach 22% of Sales at Sun Pharma AGM
Sun Pharma's 34th AGM confirmed a final dividend of ₹5.00 per share and highlighted a strong FY26 with consolidated revenues reaching ₹58,200 cr (up 11.9%). A strategic milestone was achieved as Innovative Medicines now contribute 22% of total sales, surpassing US generics in US revenue for the first time. The company also confirmed its largest-ever proposed acquisition of Organon & Co. to enter the biosimilars and women's health segments. India remains a core driver, contributing ₹19,300 cr with 14% growth and an 8.4% market share.
Confidence: HIGH
What changedShareholders formally approved the FY26 financial results, dividend, and the appointment of Dr. Andreas Busch as an Independent Director.
Why it mattersThe increasing share of innovative medicines (22%) and the massive Organon acquisition signal a structural shift toward higher-margin, specialty pharmaceutical segments, reducing reliance on volatile generic pricing.
Final Dividend: ₹5.00 per shareFY26 Revenue: ₹58,200 crInnovative Medicines % of Sales: 22%India Revenue vs Total: 33.1%R&D Expenditure: ₹3,550 cr
📅 Short termThe stock may see neutral to positive sentiment as the dividend is confirmed and the management reaffirms strong growth in the specialty segment.
📈 Long termThe pivot toward innovative medicines and the entry into biosimilars via the Organon deal are structurally positive for long-term margins and valuation.
⚠ Risk flags
- Integration risks associated with the largest-ever acquisition (Organon & Co.)
- US FDA regulatory and compliance pressures on manufacturing facilities
- Pricing pressures in the US generics market
Key Highlights
Final dividend of ₹5.00 per equity share approved for the financial year 2025-26.
Innovative Medicines now account for 22% of consolidated sales, reflecting a shift away from low-margin generics.
FY26 Consolidated Revenue grew 11.9% to ₹58,200 cr with EBITDA increasing 16.1% to ₹17,700 cr.
India business grew 14% to ₹19,300 cr, representing approximately one-third of total consolidated revenues.
R&D investment reached ₹3,550 cr, equivalent to 6.1% of total sales for the year.
👀 What to Watch
Monitor the regulatory progress and integration timeline of the Organon & Co. acquisition, as it represents the company's largest transaction and entry into biosimilars. Watch for continued growth in the specialty portfolio to offset pricing pressures in the US generics market.
₹15,180 Cr Q1 Revenue: Sun Pharma India Sales Grow 16%, Specialty Mix Hits 21.8%
Sun Pharma reported a consolidated revenue of ₹15,180 crore for Q1 FY27, a 10.1% increase year-on-year. While India formulations grew strongly by 16% to ₹5,474.9 crore, US formulation sales declined by 9.7% to $427 million due to generic pressures. The global specialty (Innovative Medicines) portfolio now contributes 21.8% of total sales, showing a structural shift. Profit After Tax stood at ₹2,890 crore, with R&D investments maintained at 5.4% of sales.
Confidence: HIGH
What changedQ1 results show a continued pivot toward specialty medicines (21.8% of sales) and robust domestic growth (16%) despite US generic headwinds.
Why it mattersThe shift to specialty products reduces reliance on the volatile US generic market and improves long-term margin stability for India's largest pharma company.
Q1 Consolidated Sales: ₹15,180 crQ1 Sales vs TTM Revenue: 25.96%India Sales Growth: 16%US Sales: $427 mnSpecialty Sales Mix: 21.8%India Market Share: 8.5%
📅 Short termThe market is likely to view the strong domestic performance and specialty ramp-up positively, offsetting the expected weakness in US generics.
📈 Long termThe structural shift towards specialty and innovative medicines (Fibromun, GL0034) remains the primary long-term value driver.
⚠ Risk flags
- US generic price erosion
- Regulatory risks at manufacturing facilities
- Execution of Organon integration
Key Highlights
Consolidated sales reached ₹15,180 crore, representing 10.1% YoY growth.
India formulation sales grew 16% YoY to ₹5,474.9 crore, capturing 8.5% market share.
US formulation sales fell 9.7% to $427 million, impacted by generic erosion including lenalidomide.
Innovative Medicines (Specialty) now accounts for 21.8% of total consolidated sales.
R&D expenditure was maintained at 5.4% of sales, with 30% dedicated to innovative medicines.
👀 What to Watch
Monitor the progress of the Organon acquisition (expected closure Q4FY27) and the PDUFA date for Ilumya (psoriatic arthritis) in October 2026.
Sun Pharma gets ANVISA approval for Semaglutide in Brazil; USD 413M market opportunity
Sun Pharmaceutical Industries has received approval from the Brazilian Health Regulatory Agency (ANVISA) to manufacture and market semaglutide injection for Type 2 diabetes. The company will launch the product in the next few days in partnership with Hypera Pharma, a leading local player. This approval targets a Brazilian semaglutide market valued at approximately USD 413 million (Rs 3,450 Cr approx.) as of June 2026. This move strengthens Sun's specialty portfolio, which currently accounts for 22% of its total sales.
Confidence: HIGH
What changedSun Pharma has secured regulatory clearance to enter the high-growth GLP-1 (semaglutide) market in Brazil, moving beyond basic generics into complex injectables.
Why it mattersBrazil is a key part of Sun's Emerging Markets strategy. Entering the USD 413 million semaglutide market allows the company to capture value in the high-demand diabetes and obesity therapeutic areas, supporting its goal of moving away from low-margin generics.
Brazil Semaglutide Market Size: USD 413 millionSpecialty Portfolio % of Sales: 22%TTM Revenue: Rs 58,462 CrMarket Opportunity vs TTM Revenue: ~6%
📅 Short termThe news is likely to be viewed positively by the market as it demonstrates Sun's ability to navigate complex regulatory approvals in the GLP-1 space, with a launch expected within days.
📈 Long termThis represents a structural step in Sun's strategy to build a high-value specialty pipeline in emerging markets, potentially improving margins over the next 2-3 years as the product ramps up.
⚠ Risk flags
- Intense competition from global innovators and other generic entrants
- Execution risk related to the partnership with Hypera Pharma
- Pricing pressures in emerging markets
Key Highlights
Targeting a Brazilian semaglutide injectable market worth approximately USD 413 million
Product launch scheduled within the next few days in partnership with Hypera Pharma
Specialty portfolio now accounts for approximately 22% of total company sales
Product to be available in two strengths: 2 mg/1.5 mL and 4 mg/3 mL multi-dose pens
Sun Pharma maintains a 100+ country footprint with a dedicated sales force of 2,900 in emerging markets
👀 What to Watch
Investors should monitor the market share gains in Brazil's chronic segment and the execution of the partnership with Hypera Pharma. Watch for the 'Emerging Markets' revenue growth in upcoming quarterly filings to quantify the impact of this launch.
Sun Pharma Partner Philogen Resubmits Nidlegy MAA to EMA with 33-Month Follow-up Data
Sun Pharma's partner, Philogen, has resubmitted the Marketing Authorization Application (MAA) for Nidlegy to the European Medicines Agency (EMA) for the treatment of locally advanced melanoma. The updated submission includes 33 months of median patient follow-up data, a significant increase from the 21 months provided in the June 2024 application. Sun Pharma holds the commercial rights for Nidlegy in Europe, New Zealand, and Australia, aligning with its strategy to grow its specialty portfolio, which currently contributes 20% of total sales. The resubmission also addresses previous regulatory queries regarding Chemistry, Manufacturing, and Controls (CMC).
Confidence: HIGH
What changedPhilogen has resubmitted the regulatory filing for Nidlegy to the EMA after addressing previous clinical and manufacturing queries with longer-term data.
Why it mattersNidlegy is a key asset in Sun Pharma's specialty pipeline for the European market. Successful commercialization would support the company's shift toward high-margin innovative medicines and away from price-sensitive generics.
Updated median follow-up: 33 monthsPrevious median follow-up: 21 monthsPhase III study enrollment: 256 patientsSpecialty portfolio share of sales: 20%TTM Revenue: Rs 58,462 Cr
📅 Short termThe resubmission is a positive procedural step that confirms the partnership's commitment to the product, likely supporting sentiment around the specialty pipeline.
📈 Long termIf approved, Nidlegy could become a meaningful contributor to Sun Pharma's European oncology business, providing a structural boost to margins over the next several years.
⚠ Risk flags
- Regulatory rejection or further information requests from the EMA
- Execution risk in commercializing a new therapy class
- Clinical trial risks for ongoing Phase III studies in other indications
Key Highlights
Updated MAA includes 33 months of median patient follow-up data, compared to 21 months in the previous 2024 submission
Phase III PIVOTAL study enrolled 256 patients across 22 clinical centers in Europe
Sun Pharma's specialty portfolio currently accounts for 20% of its Rs 58,462 Cr TTM revenue
The application targets the neoadjuvant treatment of melanoma, a segment with no currently approved drugs in this specific setting
Resubmission includes additional data from the Phase III NeoDREAM study and Phase II studies in non-melanoma skin cancer
👀 What to Watch
Investors should monitor the EMA's review timeline, as approval would allow Sun Pharma to launch a first-in-class neoadjuvant treatment in Europe. Watch for the publication of the updated Phase III data in the Journal of Clinical Oncology for further clinical validation.
Sun Pharma Receives Organon Shareholder Approval for Proposed US Acquisition
Sun Pharma has reached a major milestone in its acquisition of Organon & Co., as Organon stockholders have officially approved the merger proposal. The deal, first announced on April 27, 2026, will see Organon become a wholly-owned subsidiary of Sun Pharma's US arm. While shareholder approval is a critical step, the transaction still requires final regulatory clearances and the satisfaction of customary closing conditions. This move aligns with Sun Pharma's strategy to grow its innovative medicines portfolio, which now accounts for 22% of total sales.
Confidence: HIGH
What changedOrganon stockholders have formally approved the merger, moving the acquisition from a proposal to a near-final stage pending regulatory nods.
Why it mattersThis acquisition is a strategic move to scale Sun Pharma's specialty and innovative medicine business in the US, potentially improving long-term margins compared to standard generics.
Innovative Medicines % of Sales: 22%TTM Revenue: Rs 58,462 CrMarket Cap: Rs 4,69,506 CrInitial Announcement Date: April 27, 2026
📅 Short termThe stock is likely to react positively to the reduced deal uncertainty following the shareholder vote.
📈 Long termSuccessful integration of Organon could structurally enhance Sun Pharma's US market positioning and specialty revenue mix over the next several years.
⚠ Risk flags
- Regulatory approval delays
- Integration risks of a large US entity
Key Highlights
Organon & Co. stockholders approved the merger proposal on July 24, 2026
Global Innovative Medicines portfolio now contributes 22% to Sun Pharma's total sales
The transaction was originally initiated and announced on April 27, 2026
Sun Pharma maintains manufacturing facilities across 5 continents and serves 100+ countries
Organon will become a wholly-owned subsidiary of Sun Pharmaceutical Holdings USA, Inc.
👀 What to Watch
Investors should monitor the timeline for final regulatory approvals and the subsequent integration of Organon's portfolio into Sun Pharma's US operations.
Sun Pharma receives South Africa approval for generic Semaglutide injection
Sun Pharma has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market generic semaglutide injection for Type 2 diabetes. This is the company's second market for this product after India, highlighting its strategy to expand complex generics in emerging markets. The product will be launched in two strengths (2 mg and 4 mg) as a once-weekly injectable pen. While South Africa is a smaller market relative to Sun's Rs 58,462 Cr TTM revenue, this move targets a high-growth therapeutic segment.
Confidence: HIGH
What changedSun Pharma has secured regulatory clearance to enter the South African market with a generic version of the blockbuster GLP-1 drug, semaglutide.
Why it mattersIt demonstrates Sun Pharma's R&D capability in complex injectables and peptides, allowing it to capture market share in the high-demand diabetes segment outside of India.
Product Strengths: 2 mg/1.5 mL and 4 mg/3 mLSpecialty Portfolio % of Sales: 22%TTM Revenue: Rs 58,462 CrOperating Profit Margin: 30.3%
📅 Short termThe news is likely to be viewed positively by the market as it reinforces Sun's leadership in the complex generics space, though immediate financial impact will be limited.
📈 Long termThis is a structural step in building a global GLP-1 generic portfolio, which could become a significant revenue driver as patents expire in larger regulated markets.
⚠ Risk flags
- Competition from other generic manufacturers
- Pricing pressure in emerging markets
Key Highlights
Approval received for two strengths: 2 mg/1.5 mL and 4 mg/3 mL multi-dose injectable pens
South Africa becomes the 2nd market after India where Sun Pharma has generic semaglutide approval
Global innovative/specialty portfolio now accounts for approximately 22% of total company sales
Company maintains a leading 8.1% market share in the Indian pharmaceutical market as per recent context
👀 What to Watch
Watch for the commercial launch timeline in South Africa and potential regulatory filings for semaglutide in other emerging markets to gauge the scale of this franchise.
Sun Pharma to acquire 100% of Innovcare Lifesciences for ~Rs 271.2 Crores
Sun Pharmaceutical Industries has agreed to acquire a 100% stake in Mumbai-based Innovcare Lifesciences for approximately Rs 271.2 Crores in an all-cash deal. Innovcare is a specialized player in the marketing and distribution of pharmaceutical drugs, nutraceuticals, and cosmeceuticals, with a reported revenue of Rs 94.06 Crores for FY 2025-26. The acquisition is a strategic move to strengthen Sun Pharma's product portfolio in high-growth segments and is expected to be completed by July 31, 2026. The deal values the target at approximately 2.88 times its FY26 revenue.
Key Highlights
Acquisition of 100% outstanding shares of Innovcare Lifesciences for ~Rs 271.2 Crores cash.
Innovcare's revenue has shown steady growth from Rs 80.93 Crores in FY24 to Rs 94.06 Crores in FY26.
Strategic focus on expanding Sun Pharma's presence in the nutraceutical and cosmeceutical markets.
The transaction is expected to be completed within a short timeframe, by July 31, 2026.
No regulatory approvals are required, and it is not a related party transaction.
👀 What to Watch
Investors should view this as a positive bolt-on acquisition that enhances Sun Pharma's domestic portfolio in high-margin wellness segments. The valuation appears reasonable for a high-growth niche player, and investors should monitor the integration and its impact on the company's domestic formulation margins.
Sun Pharma Reports Arrest of Independent Director Gautam Doshi; No Impact on Operations
Sun Pharmaceutical Industries Limited has informed the stock exchanges regarding the arrest of Mr. Gautam Doshi, an Independent Director on the company's board. The company has clarified that the legal matter is personal and not connected to Sun Pharma's business or financial activities. Management expects no impact on the company's board processes or day-to-day operations. The company is monitoring the situation and will take appropriate steps based on further developments.
Key Highlights
Sun Pharma notified exchanges on June 14, 2026, regarding the arrest of Independent Director Gautam Doshi.
The company explicitly stated that the legal matter is not connected to Sun Pharma's corporate affairs.
No immediate disruption to board processes or company operations is anticipated by the management.
The company intends to monitor the legal proceedings and take necessary actions based on future updates.
👀 What to Watch
Investors should monitor for any potential resignation or further disclosures, though the event currently has no fundamental impact on the company's business operations.
Sun Pharma Sets July 7 as Record Date for ₹5 Final Dividend for FY 2025-26
Sun Pharmaceutical Industries Limited has declared a final dividend of ₹5 per equity share for the financial year 2025-26. The company has fixed July 7, 2026, as the record date to determine shareholder eligibility for the payout. The dividend is subject to approval at the 34th Annual General Meeting scheduled for July 31, 2026. Once approved, the payment will be processed on or before August 7, 2026.
Key Highlights
Final dividend of ₹5 per equity share announced for the financial year 2025-26.
Record date for dividend entitlement is fixed as Tuesday, July 7, 2026.
The 34th Annual General Meeting (AGM) will be held on July 31, 2026, at 4:00 p.m. IST.
Dividend payment will be completed by August 7, 2026, following shareholder approval.
TDS-related documents must be submitted by the record date of July 7, 2026.
👀 What to Watch
Investors should ensure they hold shares before the ex-dividend date to be eligible for the ₹5 payout. Shareholders should also update their tax residency certificates or relevant TDS documents with the RTA by July 7 to ensure appropriate tax treatment.
Sun Pharma Announces ₹5 Final Dividend; Record Date Set for July 7, 2026
Sun Pharmaceutical Industries has scheduled its 34th Annual General Meeting for July 31, 2026. The company has declared a final dividend of ₹5 per equity share for the financial year 2025-26. To be eligible for this payout, investors must hold the shares by the record date of July 7, 2026. The dividend is expected to be paid to shareholders on or before August 7, 2026, following approval at the AGM.
Key Highlights
Final dividend of ₹5 per equity share declared for the financial year 2025-26.
Record date for determining dividend eligibility is fixed as Tuesday, July 7, 2026.
The 34th Annual General Meeting (AGM) is scheduled for July 31, 2026, via Video Conferencing.
Dividend payment will be completed on or before August 7, 2026, subject to shareholder approval.
Deadline for submitting TDS-related documents is July 7, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they own the stock before the ex-dividend date. Additionally, shareholders should update their bank details and submit tax-related documents by July 7 to ensure smooth credit and appropriate tax treatment.
Sun Pharma Q4 FY26: Revenue Up 13.6%, US Innovative Portfolio Crosses $1 Billion Milestone
Sun Pharma reported a 13.6% YoY revenue growth in Q4 FY26 to INR 14,559 crore, driven by strong performance in India and Global Innovative Medicine. While EBITDA margins contracted to 27.1% due to higher US spends and lower milestone income, the full-year EBITDA margin remained healthy at 30.3%. A key milestone was achieved as the US Innovative Medicine business crossed $1 billion for the first time, now surpassing the generic business in that region. The company has guided for high single-digit top-line growth in FY27 and expects to complete the Organon acquisition by Q4 FY27.
Key Highlights
Consolidated Q4 sales grew 13.6% YoY to INR 1,45,598 million, with full-year sales reaching INR 582 billion.
Global Innovative Medicine sales grew 20.1% in Q4 to $354 million, led by Ilumya, Cequa, and Winlevi.
India formulation sales grew 14.8% in Q4, outperforming the market with a 6% volume growth versus IPM's 1.6%.
US Innovative portfolio crossed $1 billion in FY26, becoming larger than the US generic business.
Total dividend for FY26 declared at INR 16 per share, including a final dividend of INR 5 per share.
👀 What to Watch
Investors should view the growth in the high-margin specialty/innovative portfolio as a long-term value driver that offsets generic pricing pressure. Monitor the integration of the Organon acquisition in FY27 as it will be a significant catalyst for future growth.
Sun Pharma Reports 50% Response Rate in Long-Term UNLOXCYT Study for Skin Cancer
Sun Pharma announced positive long-term follow-up data for UNLOXCYT (cosibelimab-ipdl) in treating locally advanced cutaneous squamous cell carcinoma (laCSCC). The study demonstrated a 50% objective response rate, with 27% of patients achieving a complete response. Crucially, the median duration of response has not been reached after a 31-month follow-up period, indicating high durability. Safety data remained favorable, with only 2% of patients experiencing severe immune-related adverse events.
Key Highlights
Objective response rate of 50% observed in 64 patients, with 27% achieving a complete response
Median duration of response not yet reached after more than 2.5 years (31 months) of follow-up
Strong safety profile with only 1 patient (2%) experiencing Grade 3 or higher immune-related adverse events
Represents the second largest prospective study for laCSCC patients treated with PD-(L)1 monotherapy
Specialty medicines portfolio, including oncology, currently accounts for approximately 20% of total company sales
👀 What to Watch
Investors should view this as a positive development for Sun Pharma's high-margin specialty portfolio, which is a key growth driver. The durable efficacy and safety profile of UNLOXCYT strengthen its competitive position in the global oncology market.
Sun Pharma Recommends ₹5 Final Dividend; FY26 Standalone Net Profit at ₹26,234 Million
Sun Pharmaceutical Industries has recommended a final dividend of ₹5 per equity share for FY 2025-26, pending shareholder approval. On a standalone basis, the company reported a revenue of ₹2,07,546.4 million for the full year, a decline from ₹2,29,774.0 million in the previous fiscal. Net profit for the year also decreased to ₹26,234.2 million compared to ₹42,280.8 million in FY25. Despite the earnings dip, the company increased its R&D investment to ₹21,635.0 million, indicating a focus on long-term product development.
Key Highlights
Recommended final dividend of ₹5 per equity share of face value ₹1 for FY 2025-26.
Standalone FY26 Revenue from Operations stood at ₹2,07,546.4 million, down ~9.7% YoY.
Standalone Net Profit for FY26 fell to ₹26,234.2 million from ₹42,280.8 million in FY25.
R&D expenses increased to ₹21,635.0 million, up from ₹19,226.2 million in the previous year.
Standalone Basic and Diluted EPS for the full year FY26 reported at ₹10.9.
👀 What to Watch
Investors should weigh the steady dividend payout against the decline in standalone profitability and monitor consolidated results for a comprehensive view of global performance. The rising R&D expenditure suggests a commitment to future growth through innovation.
Sun Pharma Q4 FY26 Standalone PAT Drops to ₹608.7 Cr; Recommends ₹5 Final Dividend
Sun Pharmaceutical Industries reported a standalone profit after tax of ₹6,087 million for Q4 FY26, a sharp decline from ₹20,419.7 million in the same quarter last year. For the full year FY26, standalone revenue from operations stood at ₹207,546.4 million, down from ₹229,774 million in FY25. Despite the lower earnings, the Board has recommended a final dividend of ₹5 per share. The annual results were impacted by exceptional items totaling ₹5,463.4 million.
Key Highlights
Recommended a final dividend of ₹5 per equity share of face value ₹1 for FY 2025-26.
Standalone Q4 FY26 revenue from operations decreased to ₹49,238.8 million from ₹71,794.5 million YoY.
Full-year standalone profit after tax fell to ₹26,234.2 million in FY26 compared to ₹42,280.8 million in FY25.
Research and Development (R&D) expenses for FY26 increased to ₹21,635.0 million from ₹19,226.2 million in the previous year.
Total standalone income for the full year FY26 was ₹211,739.7 million versus ₹233,565.4 million in FY25.
👀 What to Watch
Investors should exercise caution as standalone profits and revenues show a significant year-on-year decline; it is critical to review the consolidated results for the full global performance impact. The ₹5 dividend provides some yield support, but the underlying growth trajectory requires further scrutiny.
Sun Pharma Appoints R&D Veteran Dr. Andreas Busch as Independent Director for 5-Year Term
Sun Pharmaceutical Industries has appointed Dr. Andreas Busch as an Independent Director for a five-year term starting May 12, 2026. Dr. Busch is a global leader in drug discovery with experience at Sanofi, Bayer, and Shire, having led over 15 drugs to FDA approval. Concurrently, Ms. Satyavati Berera joins the Audit and Risk Management Committees, while Ms. Rama Bijapurkar will retire on May 20, 2026. These appointments significantly strengthen the board's technical expertise and governance framework.
Key Highlights
Dr. Andreas Busch appointed as Independent Director for a 5-year term effective May 12, 2026.
Dr. Busch has a track record of leading over 15 commercial drugs from discovery to FDA approval.
Ms. Satyavati Berera inducted into the Audit Committee and Risk Management Committee.
Ms. Rama Bijapurkar to retire from the Board on May 20, 2026, following the completion of her term.
👀 What to Watch
Investors should view the addition of a world-renowned R&D expert to the board as a positive signal for Sun Pharma's long-term innovation pipeline. No immediate portfolio changes are necessary based on this governance update.
Sun Pharma Ratings Reaffirmed at AAA; CRISIL Places Long-term Rating on Watch
CRISIL and ICRA have reaffirmed Sun Pharma's highest credit ratings of 'AAA' for long-term and 'A1+' for short-term facilities. CRISIL has placed the long-term rating on 'Rating Watch with Developing Implications' following the company's April 27, 2026, announcement to acquire Organon & Co. ICRA, however, has maintained its 'Stable' outlook while reaffirming the ratings. This indicates a period of assessment for the company's capital structure following the significant acquisition.
Key Highlights
CRISIL reaffirmed long-term bank facilities at 'CRISIL AAA' and short-term facilities at 'CRISIL A1+'
ICRA reaffirmed long-term rating at '[ICRA]AAA(Stable)' and short-term rating at '[ICRA]A1+'
CRISIL placed the 'CRISIL AAA' rating on 'Rating Watch with Developing Implications' following the Organon & Co. acquisition
The rating watch follows the definitive agreement signed on April 27, 2026, to acquire Organon & Co.
👀 What to Watch
Investors should monitor the final rating action from CRISIL once the Organon & Co. acquisition is completed to understand the impact on debt levels. The reaffirmation of AAA ratings suggests the company maintains a very strong credit profile despite the expansion.
